Merck Serono’s grants programme to fund scientific innovation

Merck Serono, the biopharmaceutical division of Merck, has launched Merck Global Grants, a programme that underscores the company’s commitment to funding scientific innovation and independent medical education around the world. The initiative encompasses Merck Serono’s complete grants portfolio, including the Grants for Innovation in Research and Grants for Independent Medical Education.

The programme totals an annual investment of Euro 20 million across all grants programmes, highlighting the company’s efforts to promote advances in the field of medicine, addressing recognised gaps in healthcare knowledge, and improving the quality of patient care.

“Merck Serono has a long-standing reputation as a strong advocate for scientific innovation and medical education, believing that both are integral to helping healthcare professionals bring enhanced care to patients,” said Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at Merck Serono.

The Grants for Innovation in research identify and fund promising research from across biopharma, including academia, research centres, smaller start-ups and independent researchers. Specific grants focus on areas in which Merck Serono has a strong R&D and commercial presence, including the Grant for Oncology Innovation, Grant for Multiple Sclerosis Innovation, Grant for Fertility Innovation, and Grant for Growth Innovation.

The Grants for Independent Medical Education foster the advancement of medicine, and address recognised gaps in healthcare knowledge, in order to improve patient care. The programme includes the launch of an online portal which allows highly transparent and ethical interactions with medical education providers and represents an important milestone in the Merck Serono Medical Education Strategy. Funding is provided to educational institutions such as universities, medical education providers, medical scientists and scientific organisations.

EP News BureauMumbai

Comments (0)
Add Comment